Cranberry tablets
Cranberry allergenic extract is used in allergenic testing.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Cranberry
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
5 branded products available
Part of the Cymalon brand family (generic: Cranberry)
MHRA licensed products
View all licensed products for Cranberry on the MHRA register
Numark Concentrated Cranberry extract 5000mg tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
Urinary tract infection (lower): antimicrobial prescribing (NG109)
Urinary tract infection (catheter-associated): antimicrobial prescribing (NG113)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 26 · Randomised trials: 14 · 2014–2026
Showing the 50 most relevant studies, sorted by most relevant.
M. Paquette, Ana S. Medina Larqué, S. Weisnagel, et al.
The British Journal of Nutrition, 2017
Jiayue Xia, Chao Yang, Deng-feng Xu, et al.
PLoS ONE, 2021
D. Rocha, A. Caldas, B. P. da Silva, et al.
Critical Reviews in Food Science and Nutrition, 2019
Bahreyni LZ, Amini MR, Sheikhi L, et al.
2026
- Vaccinium macrocarpon
- Hypertension
- Blood Pressure
BackgroundThe aim of this paper, which includes a meta-analysis, is to elucidate the effects of cranberry consumption on systolic and diastolic blood pressure based on all relevant randomized controlled trials (RCTs).Materials and methodsA systematic literature search was performed across the ISI Web of Science, PubMed, Embase, the Cochrane Library, and Google Scholar databases, encompassing trials published until December 2024. Weighted mean differences (WMD) were calculated using random or fixed-effects models. Between-study heterogeneity was evaluated using Cochrane's test and the I² index. This study's registration number in PROSPERO is CRD420251028424.ResultsA total of 1204 publications were reviewed, leading to the inclusion of 12 trials for qualitative synthesis and meta-analysis. The pooled effect size indicated statistically nonsignificant reductions of 1.31 mmHg for systolic blood pressure (SBP) (p = 0.19) and 1.31 mmHg for diastolic blood pressure (DBP) (p = 0.12). Stratified analysis showed that the reduction in SBP was statistically significant in studies where cranberry was provided in juice form, with a duration of 8 weeks or less, involving participants with a mean age of ConclusionThis systematic review and meta-analysis suggest that cranberry consumption was not effective in managing SBP and DBP.
Abstract licence: CC BY
Xu J, Li C, Wu W, et al.
2025
- Vaccinium macrocarpon
- Plant Extracts
- Fruit
Cranberry (Vaccinium macrocarpon Ait.) is an herbaceous, evergreen, dwarf shrub of the genus Vaccinium in the family Ericaceae, often used as a functional food. Cranberries are primarily distributed in the northern United States-including Massachusetts, Wisconsin, and Maine-as well as in Quebec, Canada; the state of Columbia; Chile in South America; and northeastern Europe. They are also found in China's Greater Khingan Range and Fuyuan City, Jiamusi, Heilongjiang Province. The plants thrive in cool environments and exhibit considerable adaptability to soil conditions, preferring acidic soils. Cranberries are rich in a variety of biologically active components, such as polyphenols (proanthocyanidins, chlorogenic acid, flavonols, anthocyanins, caffeic acid, etc.), triterpenoids, and other nutrients. Studies have shown that the chemical components extracted from cranberry fruit have pharmacological effects such as antioxidant, anti-inflammatory, anti-cancer, and urinary tract infection prevention and treatment, and are commonly used clinically in the treatment of cardiovascular diseases, the prevention of urinary tract infections, blood pressure lowering, and the fight against Helicobacter pylori, among other clinical diseases. Cranberries also play a huge role in daily nutrition, and they are named for their richness in a variety of mineral elements, trace elements and vitamins. This work uses information from Pubmed, Web of Science, Scopus, CNKI (China National Knowledge Infrastructure), and related papers. In this paper, a comprehensive review of the phytochemical composition, pharmacological mechanism of action, clinical application value and nutritional significance of cranberry was conducted in recent years to provide references for the further extraction of chemical components in cranberry and rational clinical application, which can help to guide people to rationalize their diets and promote the formation of healthy diets.
Abstract licence: CC BY
Tavakoli S, Ghaemi S, Amini MR, et al.
2026
Weese JS, Weese HE
2026
- Vaccinium macrocarpon
- Urinary Tract Infections
- Cat Diseases
Amini MR, Elahikhah M, Etesamnia S, et al.
2026
M. Pourmasoumi, A. Hadi, Ameneh Najafgholizadeh, et al.
Clinical nutrition, 2020
R. Feliciano, C. Mills, Geoffrey Istas, et al.
Nutrients, 2017
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Cranberry
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72